Outcome of Patients With Metastatic Triple Negative Breast Cancer Treated With First-Line Chemotherapy: A Single Institution Retrospective Analysis

Metastatic triple negative breast cancer (mTNBC) is associated with poor prognosis and limited treatment options. It is known to be high immunogenic, with a high level of programmed cell death-ligand 1 (PD-L1) expression. PD-L1 expression in TNBC does not have a clear prognostic relevance. In this study, the authors aimed to assess survival outcomes according to PD-L1 expression in the real world.